Joseph Patrick Erinjeri, Muhammad S. Beg, Mohamed Bouattour, Zhenggang Ren, Bruno Sangro, Stephen Lam Chan, Valeriy Vladimirovich Breder, Chang-Fang Chiu, Thomas Decaens, Jeong Heo, Rebecca Griffin, Sajid Ali, Kavitha Balaji, Masatoshi Kudo. "Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.4083